Crossing the Blood-Brain Barrier



Targeted Brain Delivery of Therapeutics


Our TXP1 Brain Shuttle Enhances Delivery of Therapeutic Payloads to the Brain by >30-fold

Ready for Clinical Application

TXP1

Brain Shuttle

Based on the Deimmunised VNAR Antibody Scaffold and Targeting TfR1 for Efficient Receptor Mediated Transcytosis Across the Blood-Brain Barrier

High Brain Delivery

Improves delivery of therapeutics across the BBB to the brain parenchyma in primates by >30-fold

Brain Specific

Brain specific delivery with no accumulation in liver, spleen, lung, kidney or muscle

Cross-Species Reactive

Cross reactive with human receptor for easy clinical translation

Optimal Format

Optimised fusion formats for maximum activity

Optimal Binding

Optimised receptor binding kinetics for efficient transcytosis across the BBB

Deimmunised

Based on the deimmunised VNAR antibody scaffold

Lasting

Prolonged brain exposure and slow blood clearance at low doses

Opportunities Beyond the Blood-Brain Barrier


Pipeline

Delivery of Therapeutics Across the Blood-Brain Barrier Presents New Opportunities for the Next Generation of CNS Therapies

Leadership Team

Following the Science

Frank S Walsh

CEO (Founder)

J Lynn Rutkowski

CSO (Founder)

example@mail.com
More

Steve Moore

COO

example@mail.com
More

Pawel Stocki

VP Research

Board of Directors

Experience and Skill

Mike J Owen

Chairman

Frank S Walsh

CEO

Our Partners